Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction

被引:36
作者
Kristensen, Soren L. [1 ,2 ]
Jhund, Pardeep S. [1 ]
Kober, Lars [3 ]
Preiss, David [1 ]
Kjekshus, John [4 ]
McKelvie, Robert S. [5 ]
Zile, Michael R. [6 ,7 ]
Anand, Inder S. [8 ,9 ]
Wikstrand, John [10 ]
Wedel, Hans [11 ]
Komajda, Michel [12 ,13 ]
Carson, Peter E. [14 ,15 ]
Cleland, John G. F. [16 ,17 ]
McMurray, John J. V. [1 ]
机构
[1] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland
[2] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark
[3] Univ Copenhagen, Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark
[4] Univ Oslo, Rikshosp, Dept Cardiol, N-0027 Oslo, Norway
[5] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada
[6] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA
[7] Med Univ S Carolina, Charleston, SC 29425 USA
[8] Vet Affairs Med Ctr, Minneapolis, MN USA
[9] Univ Minnesota, Minneapolis, MN USA
[10] Gothenburg Univ, Wallenberg Lab Cardiovasc Res, Sahlgrenska Acad, Gothenburg, Sweden
[11] Nord Sch Publ Hlth, Gothenburg, Sweden
[12] Univ Paris 06, Hosp Pitie Salpetriere, Paris, France
[13] Inst ICAN, Paris, France
[14] Georgetown Univ, Washington, DC USA
[15] Washington DC Vet Affairs Med Ctr, Washington, DC USA
[16] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England
[17] Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Natl Heart & Lung Inst, London, England
关键词
Heart failure; Clinical trials; HF-PEF; HF-REF; Mortality; ROSUVASTATIN; TRIAL; PROGRESSION; IRBESARTAN; DESIGN; CORONA;
D O I
10.1002/ejhf.211
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo investigate the prognostic significance of hospitalization for worsening heart failure (WHF), myocardial infarction (MI), and stroke in patients with chronic heart failure (HF). Methods and resultsWe studied 5011 patients with HF and reduced EF (HF-REF) in the CORONA trial and 4128 patients with HF and preserved EF (HF-PEF) in the I-Preserve trial. Adjusted hazard ratios (HRs) for death were estimated for 0-30 days and 31 days after first post-randomization WHF, MI, or stroke used as a time-dependent variable, compared with patients with none of these events. In CORONA, 1616 patients (32%) had post-randomization first events (1223 WHF, 216 MI, 177 stroke), and the adjusted HR for mortality 30 days after an event was: WHF 7.21 [95% confidence interval (CI) 2.05-25.40], MI 23.08 (95% CI 6.44-82.71), and stroke 32.15 (95% CI 8.93-115.83). The HR for mortality at >30 days was: WHF 3.62 (95% CI 3.11-4.21), MI 4.41 (95% CI 3.23-6.02), and stroke 3.19 (95% CI 2.21-4.61). In I-Preserve, 896 patients (22%) experienced a post-randomization event (638 WHF, 111 MI, 147 stroke). The HR for mortality 30 days was WHF 31.77 (95% CI 7.60-132.81), MI 154.77 (95% CI 34.21-700.17), and stroke 223.30 (95% CI 51.42-969.78); for >30 days it was WHF 3.36 (95% CI 2.79-4.05), MI 3.29 (95% CI 2.14-5.06), and stroke 5.13 (95% CI 3.61-7.29). ConclusionsIn patients with both HF-REF and HF-PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 17 条
[1]   The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: Rationale and design [J].
Carson, P ;
Massie, BM ;
McKelvie, R ;
McMurray, J ;
Komajda, M ;
Zile, M ;
Ptaszynska, A ;
Frangin, G .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (08) :576-585
[2]   Cardiovascular critical event pathways for the progression of heart failure -: A report from the ATLAS study [J].
Cleland, JGF ;
Thygesen, K ;
Uretsky, BF ;
Armstrong, P ;
Horowitz, JD ;
Massie, B ;
Packer, M ;
Poole-Wilson, PA ;
Rydén, L .
EUROPEAN HEART JOURNAL, 2001, 22 (17) :1601-1612
[3]   Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association [J].
Heidenreich, Paul A. ;
Trogdon, Justin G. ;
Khavjou, Olga A. ;
Butler, Javed ;
Dracup, Kathleen ;
Ezekowitz, Michael D. ;
Finkelstein, Eric Andrew ;
Hong, Yuling ;
Johnston, S. Claiborne ;
Khera, Amit ;
Lloyd-Jones, Donald M. ;
Nelson, Sue A. ;
Nichol, Graham ;
Orenstein, Diane ;
Wilson, Peter W. F. ;
Woo, Y. Joseph .
CIRCULATION, 2011, 123 (08) :933-944
[4]   Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges [J].
Khand, AU ;
Gemmell, I ;
Rankin, AC ;
Cleland, JGF .
EUROPEAN HEART JOURNAL, 2001, 22 (02) :153-164
[5]   A statin in the treatment of heart failure?: Controlled rosuvastatin multinational study in heart failure (CORONA):: Study design and baseline characteristics [J].
Kjekshus, J ;
Dunselman, P ;
Blideskog, M ;
Eskilson, C ;
Hjalmarson, Å ;
McMurray, JV ;
Waagstein, F ;
Wedel, H ;
Wessman, P ;
Wikstrand, J .
EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (06) :1059-1069
[6]   Rosuvastatin in older patients with systolic heart failure [J].
Kjekshus, John ;
Apetrei, Eduard ;
Barrios, Vivencio ;
Boehm, Michael ;
Cleland, John G. F. ;
Cornel, Jan H. ;
Dunselman, Peter ;
Fonseca, Candida ;
Goudev, Assen ;
Grande, Peer ;
Gullestad, Lars ;
Hjalmarson, Ake ;
Hradec, Jaromir ;
Janosi, Andras ;
Kamensky, Gabriel ;
Komajda, Michel ;
Korewicki, Jerzy ;
Kuusi, Timo ;
Mach, Francois ;
Mareev, Vyacheslav ;
McMurray, John J. V. ;
Ranjith, Naresh ;
Schaufelberger, Maria ;
Vanhaecke, Johan ;
van Veldhuisen, Dirk J. ;
Waagstein, Finn ;
Wedel, Hans ;
Wikstrand, John .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2248-2261
[7]   Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) [J].
Komajda, Michel ;
Carson, Peter E. ;
Hetzel, Scott ;
McKelvie, Robert ;
McMurray, John ;
Ptaszynska, Agata ;
Zile, Michael R. ;
DeMets, David ;
Massie, Barry M. .
CIRCULATION-HEART FAILURE, 2011, 4 (01) :27-U73
[8]   Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. [J].
Massie, Barry M. ;
Carson, Peter E. ;
McMurray, John J. ;
Komajda, Michel ;
McKelvie, Robert ;
Zile, Michael R. ;
Anderson, Susan ;
Donovan, Mark ;
Iverson, Erik ;
Staiger, Christoph ;
Ptaszynska, Agata .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) :2456-2467
[9]   Epidemiology, aetiology, and prognosis of heart failure [J].
McMurray, JJ ;
Stewart, S .
HEART, 2000, 83 (05) :596-602
[10]   International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial [J].
Mentz, Robert J. ;
Cotter, Gad ;
Cleland, John G. F. ;
Stevens, Susanna R. ;
Chiswell, Karen ;
Davison, Beth A. ;
Teerlink, John R. ;
Metra, Marco ;
Voors, Adriaan A. ;
Grinfeld, Liliana ;
Ruda, Mikhail ;
Mareev, Viacheslav ;
Lotan, Chaim ;
Bloomfield, Daniel M. ;
Fiuzat, Mona ;
Givertz, Michael M. ;
Ponikowski, Piotr ;
Massie, Barry M. ;
O'Connor, Christopher M. .
EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (06) :614-624